Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
BLyS/BAFF Inhibitor (Anti-B-Lymphocyte Stimulator)

Belimumab (Cutaneous Lupus)

Brand names: Benlysta

Belimumab is a monoclonal antibody used as add-on therapy in active autoantibody-positive systemic lupus erythematosus, including patients with cutaneous lupus manifestations.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds and inhibits soluble B-lymphocyte stimulator (BLyS/BAFF), reducing survival of autoreactive B cells and autoantibody production.

Prescribing in practice

  • Serious and sometimes fatal infections can occur, so do not start during active infection and monitor closely throughout treatment.
  • Hypersensitivity and infusion or injection reactions can occur, including delayed reactions, so observe accordingly.
  • Depression and mood changes have been reported and should be assessed before and during treatment.

Monitoring

Monitor for infection, infusion or injection-site reactions and new or worsening mood disturbance during therapy.

Counselling the patient

  • Report fever or other signs of infection promptly.
  • Tell your team about any new low mood or anxiety.
  • Avoid live vaccines while receiving treatment.

Evidence & guidelines

Belimumab is recommended by NICE as an add-on option for certain patients with active autoantibody-positive systemic lupus erythematosus.

Reference: BLISS-76 trial (Furie et al. 2011); BLISS-52 trial (Navarra et al. NEJM 2011); NICE TA397; MHRA SPC Benlysta; BSR/BHPR Lupus Guidelines (2022); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways